The emerging CAR-T cell therapy, CT041, shows potential in treating advanced pancreatic cancer (PC). This phase I/Ib trial pooled analysis evaluated the safety and efficacy of CT041 in 24 patients with advanced PC. The results demonstrated a median overall survival (mOS) of 10.0 months and a median progression-free survival (mPFS) of 3.3 months.
The most common adverse events were grade 3 or higher hematologic toxicities, cytokine release syndrome (CRS), and gastrointestinal disorders. Despite these side effects, the overall response rate was 16.7%, with a disease control rate of 70.8%. Notably, 70.8% of patients experienced at least a 30% reduction in CA19-9 levels.
These findings suggest that CT041 offers a tolerable safety profile and promising anticancer efficacy. Further studies are needed to confirm these benefits and establish long-term outcomes.
Key Points:
CT041 demonstrated a mOS of 10.0 months and mPFS of 3.3 months in advanced PC.
Common side effects: hematologic toxicities, CRS, and GI disorders.
High disease control rate (70.8%) and significant CA19-9 level reduction.
For more details, read the full study: DOI: 10.1245/s10434-024-15449-9.
Leave a Reply